The patient incidence of motesanib-related adverse events in general and, more specifically, events commonly associated with VEGF(R) inhibitor therapy, such as hypertension or bleeding events [5, 21, 25, 26], was comparable across dose cohorts and similar to what has been reported in other motesanib monotherapy and combination studies [14–16]. Here, VEGFA is linked to hypertensive disorder.